Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Bladder Cancer

  Free Subscription


01.08.2022

1 Acta Biochim Biophys Sin (Shanghai)
2 Acta Oncol
2 Biomedicines
1 Bladder Cancer
1 BMC Cancer
1 BMC Urol
1 Cancer J
2 Cancers (Basel)
1 Cell Cycle
6 Clin Genitourin Cancer
1 Curr Opin Urol
2 Diagnostics (Basel)
1 Eur J Nucl Med Mol Imaging
1 Front Genet
2 Front Immunol
1 Funct Integr Genomics
2 Future Oncol
1 Indian J Pathol Microbiol
1 Int J Biol Sci
5 Int J Mol Sci
1 J Cannabis Res
1 J Immunol
1 J Sex Med
1 J Transl Med
1 J Urol
1 JAMA Oncol
1 Life (Basel)
1 Medicina (Kaunas)
1 Mol Med Rep
1 Nutr Cancer
1 PLoS One
1 Pract Radiat Oncol
2 Urologia


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Biochim Biophys Sin (Shanghai)

  1. WU L, Yang Z, Dai G, Fan B, et al
    SOX5 promotes cell growth and migration through modulating the DNMT1/p21 pathway in bladder cancer.
    Acta Biochim Biophys Sin (Shanghai). 2022;54:1-12.
    PubMed         Abstract available


    Acta Oncol

  2. UDUMYAN R, Botteri E, Jerlstrom T, Montgomery S, et al
    Beta-blocker use and urothelial bladder cancer survival: a Swedish register-based cohort study.
    Acta Oncol. 2022 Jul 26:1-9. doi: 10.1080/0284186X.2022.2101902.
    PubMed         Abstract available

  3. VERSCHOOR N, Heemsbergen WD, Boormans JL, Franckena M, et al
    Bladder-sparing (chemo)radiotherapy in elderly patients with muscle-invasive bladder cancer: a retrospective cohort study.
    Acta Oncol. 2022 Jul 26:1-7. doi: 10.1080/0284186X.2022.2101381.
    PubMed         Abstract available


    Biomedicines

  4. MANSOUR B, Monyok A, Gajdacs M, Stercz B, et al
    Bladder Tissue Microbiome Composition in Patients of Bladder Cancer or Benign Prostatic Hyperplasia and Related Human Beta Defensin Levels.
    Biomedicines. 2022;10.
    PubMed         Abstract available

  5. MIN K, Kim HT, Lee EH, Park H, et al
    Bacteria for Treatment: Microbiome in Bladder Cancer.
    Biomedicines. 2022;10.
    PubMed         Abstract available


    Bladder Cancer

  6. MEGHANI K, Folgosa Cooley L, Piunti A, Meeks JJ, et al
    Role of Chromatin Modifying Complexes and Therapeutic Opportunities in Bladder Cancer.
    Bladder Cancer. 2022;8:101-112.
    PubMed         Abstract available


    BMC Cancer

  7. LIN Q, Pei L, Zhao Z, Zhuang X, et al
    Glycoprotein alpha-Subunit of Glucosidase II (GIIalpha) is a novel prognostic biomarker correlated with unfavorable outcome of urothelial carcinoma.
    BMC Cancer. 2022;22:817.
    PubMed         Abstract available


    BMC Urol

  8. QING L, Li Q, Yang Y, Xu W, et al
    A prognosis marker MUC1 correlates with metabolism and drug resistance in bladder cancer: a bioinformatics research.
    BMC Urol. 2022;22:114.
    PubMed         Abstract available


    Cancer J

  9. ALKHOULI MA, Bazargan S, Pilon-Thomas S, Poch M, et al
    Current State of Cell Therapies for Genitourinary Malignancies.
    Cancer J. 2022;28:294-300.
    PubMed         Abstract available


    Cancers (Basel)

  10. SARAFIDIS M, Lambrou GI, Zoumpourlis V, Koutsouris D, et al
    An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available

  11. LIU YL, Wu CT, Hsu YC, Chen MF, et al
    Perioperative Complications and Oncologic Outcomes after Radical Cystectomy in End-Stage Renal Disease Patients with Bladder Cancer Obtained Using a Standardized Reporting System.
    Cancers (Basel). 2022;14.
    PubMed         Abstract available


    Cell Cycle

  12. DING K, Zheng Z, Han Y, Huang X, et al
    Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer.
    Cell Cycle. 2022 Jul 27:1-17. doi: 10.1080/15384101.2022.2103898.
    PubMed         Abstract available


    Clin Genitourin Cancer

  13. MARTINI A, Lonati C, Necchi A, Galsky MD, et al
    Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival.
    Clin Genitourin Cancer. 2022;20:389.
    PubMed         Abstract available

  14. CORSI NJ, Messing EM, Sood A, Keeley J, et al
    Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis.
    Clin Genitourin Cancer. 2022 Jun 25. pii: S1558-7673(22)00140.
    PubMed         Abstract available

  15. VOLZ Y, Eismann L, Pfitzinger P, Westhofen T, et al
    Long-term Health-related Quality of Life (HRQOL) After Radical Cystectomy and Urinary Diversion - A Propensity Score-matched Analysis.
    Clin Genitourin Cancer. 2022;20:e283-e290.
    PubMed         Abstract available

  16. RAGONESE M, Gianfrancesco LD, Palermo G, Pierconti F, et al
    The Role of Bladder Epicheck Test In Follow-Up of Patients with Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2022;20:e271-e275.
    PubMed         Abstract available

  17. ABRATE A, Sessa F, Sessa M, Campi R, et al
    Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:381-387.
    PubMed         Abstract available

  18. RICHTERS A, Kiemeney LALM, Mehra N, Westgeest HM, et al
    Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2022;20:e346-e352.
    PubMed         Abstract available


    Curr Opin Urol

  19. VON DEIMLING M, Pallauf M, Bianchi A, Laukhtina E, et al
    Active surveillance for non-muscle-invasive bladder cancer: fallacy or opportunity?
    Curr Opin Urol. 2022 Jul 25. pii: 00042307-990000000-00032.
    PubMed         Abstract available


    Diagnostics (Basel)

  20. MURESU N, Di Lorenzo B, Saderi L, Sechi I, et al
    Prevalence of Human Papilloma Virus Infection in Bladder Cancer: A Systematic Review.
    Diagnostics (Basel). 2022;12.
    PubMed         Abstract available

  21. CHEN R, Pagano I, Sun Y, Murakami K, et al
    A Diagnostic Gene Expression Signature for Bladder Cancer Can Stratify Cases into Prescribed Molecular Subtypes and Predict Outcome.
    Diagnostics (Basel). 2022;12.
    PubMed         Abstract available


    Eur J Nucl Med Mol Imaging

  22. UNTERRAINER LM, Lindner S, Eismann L, Casuscelli J, et al
    Feasibility of [(68)Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma.
    Eur J Nucl Med Mol Imaging. 2022;49:3571-3580.
    PubMed         Abstract available


    Front Genet

  23. RAO X, Cao H, Yu Q, Ou X, et al
    NEAT1/MALAT1/XIST/PKD--Hsa-Mir-101-3p--DLGAP5 Axis as a Novel Diagnostic and Prognostic Biomarker Associated With Immune Cell Infiltration in Bladder Cancer.
    Front Genet. 2022;13:892535.
    PubMed         Abstract available


    Front Immunol

  24. XU W, Tang HJ, Anwaier A, Liu W, et al
    Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer.
    Front Immunol. 2022;13:909324.
    PubMed         Abstract available

  25. SUN JX, Liu CQ, Xu JZ, An Y, et al
    A Four-Cell-Senescence-Regulator-Gene Prognostic Index Verified by Genome-Wide CRISPR Can Depict the Tumor Microenvironment and Guide Clinical Treatment of Bladder Cancer.
    Front Immunol. 2022;13:908068.
    PubMed         Abstract available


    Funct Integr Genomics

  26. WANG L, Wang Y, Bi J
    In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer.
    Funct Integr Genomics. 2022 Jul 28. pii: 10.1007/s10142-022-00884.
    PubMed         Abstract available


    Future Oncol

  27. SATKUNASIVAM R, Lim K, Teh BS, Guzman J, et al
    A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC: the RAD VACCINE MIBC trial.
    Future Oncol. 2022;18:2771-2781.
    PubMed         Abstract available

  28. SONG Y, Tian J, Yang L, Zhang Y, et al
    Prognostic value of preoperative platelet-related parameters and plasma fibrinogen in patients with non-muscle invasive bladder cancer after transurethral resection of bladder tumor.
    Future Oncol. 2022 Jul 26. doi: 10.2217/fon-2022-0223.
    PubMed         Abstract available


    Indian J Pathol Microbiol

  29. ARSLAN AI, Karabag S, Akgul M
    Effect of HER2 and Fascin expression on muscle-invasive bladder cancers: Classification by basaloid and luminal phenotypes.
    Indian J Pathol Microbiol. 2022;65:604-609.
    PubMed         Abstract available


    Int J Biol Sci

  30. FAN T, Li S, Xiao C, Tian H, et al
    CCL20 promotes lung adenocarcinoma progression by driving epithelial-mesenchymal transition.
    Int J Biol Sci. 2022;18:4275-4288.
    PubMed         Abstract available


    Int J Mol Sci

  31. ZUPANCIC D, Veranic P
    Nanodiamonds as Possible Tools for Improved Management of Bladder Cancer and Bacterial Cystitis.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  32. ECKE TH, Voss PC, Schlomm T, Rabien A, et al
    Prediction of Response to Cisplatin-Based Neoadjuvant Chemotherapy of Muscle-Invasive Bladder Cancer Patients by Molecular Subtyping including KRT and FGFR Target Gene Assessment.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  33. SANGUEDOLCE F, Zanelli M, Palicelli A, Ascani S, et al
    Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  34. SANGUEDOLCE F, Zanelli M, Palicelli A, Ascani S, et al
    Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available

  35. CHAN KM, Vasilev K, MacGregor M
    Effects of Supplemental Drugs on Hexaminolevulinate (HAL)-Induced PpIX Fluorescence in Bladder Cancer Cell Suspensions.
    Int J Mol Sci. 2022;23.
    PubMed         Abstract available


    J Cannabis Res

  36. TOMKO AM, Whynot EG, Dupre DJ
    Anti-cancer properties of cannflavin A and potential synergistic effects with gemcitabine, cisplatin, and cannabinoids in bladder cancer.
    J Cannabis Res. 2022;4:41.
    PubMed         Abstract available


    J Immunol

  37. DOMINGUEZ-GUTIERREZ PR, Kwenda EP, Donelan W, Miranda M, et al
    Detection of PD-L1-Expressing Myeloid Cell Clusters in the Hyaluronan-Enriched Stroma in Tumor Tissue and Tumor-Draining Lymph Nodes.
    J Immunol. 2022;208:2829-2836.
    PubMed         Abstract available


    J Sex Med

  38. JUBBER I, Rogers Z, Catto JW, Bottomley S, et al
    Sexual Activity, Function and Dysfunction After a Diagnosis of Bladder Cancer.
    J Sex Med. 2022 Jul 20. pii: S1743-6095(22)01504.
    PubMed         Abstract available


    J Transl Med

  39. LIM LM, Chung WY, Hwang DY, Yu CC, et al
    Whole-exome sequencing identified mutational profiles of urothelial carcinoma post kidney transplantation.
    J Transl Med. 2022;20:324.
    PubMed         Abstract available


    J Urol

  40. MCELREE IM, Steinberg RL, Martin AC, Richards J, et al
    Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guerin-Naive High-Risk Nonmuscle-Invasive Bladder Cancer.
    J Urol. 2022 Jul 27:101097JU0000000000002740. doi: 10.1097/JU.0000000000002740.
    PubMed         Abstract available


    JAMA Oncol

  41. NIMGAONKAR V, Hubbard RA, Carpenter EL, Mamtani R, et al
    Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy.
    JAMA Oncol. 2022;8:1070-1072.
    PubMed        


    Life (Basel)

  42. LIM EC, Lim SW, Tan KJ, Sathiya M, et al
    In-Silico Analysis of Deleterious SNPs of FGF4 Gene and Their Impacts on Protein Structure, Function and Bladder Cancer Prognosis.
    Life (Basel). 2022;12.
    PubMed         Abstract available


    Medicina (Kaunas)

  43. BECATTINI L, Saieva C, Doni L, Roviello G, et al
    Gender and Advanced Urothelial Cancer: Outcome, Efficacy and Toxicity following Chemotherapy.
    Medicina (Kaunas). 2022;58.
    PubMed         Abstract available


    Mol Med Rep

  44. WU D, Niu X, Pan H, Zhou Y, et al
    [Corrigendum] MicroRNA335 is downregulated in bladder cancer and inhibits cell growth, migration and invasion via targeting ROCK1.
    Mol Med Rep. 2022;26.
    PubMed         Abstract available


    Nutr Cancer

  45. LIU J, Wu P, Lai S, Song X, et al
    Clinicopathological and Prognostic Significance of Preoperative Prognostic Nutritional Index in Patients with Upper Urinary Tract Urothelial Carcinoma.
    Nutr Cancer. 2022;74:2964-2974.
    PubMed         Abstract available


    PLoS One

  46. DE WISPELAERE N, Rico SD, Bauer M, Luebke AM, et al
    High prevalence of p16 staining in malignant tumors.
    PLoS One. 2022;17:e0262877.
    PubMed         Abstract available


    Pract Radiat Oncol

  47. PREYRA B, Cury FL, Katib Y, Monsoor M, et al
    The rate of prostatic involvement in men treated with radical cystectomy for muscle invasive bladder cancer.
    Pract Radiat Oncol. 2022 Jul 25. pii: S1879-8500(22)00193.
    PubMed         Abstract available


    Urologia

  48. SATO R, Watanabe K, Matsushita Y, Watanabe H, et al
    Prognostic assessments in patients with upper tract urothelial carcinoma undergoing radical nephroureterectomy and systematic regional lymph node dissection.
    Urologia. 2022;89:354-357.
    PubMed         Abstract available

  49. IKEDA Y, Hamada M, Matsumi Y, Sekimoto M, et al
    Use of ileal bypass in the surgical management of two rare cases of ileal-neobladder fistula in patients who underwent radical cystectomy.
    Urologia. 2022;89:488-492.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: